Clinical Trial

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated August 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-17; most recent amendment 2026-01-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-23
Trial Details
NCT Number NCT07243171
Lead Sponsor Hangzhou Sciwind Biosciences Co., Ltd.
Conditions Overweight and/or Obesity, Weight Management
Enrollment 84 participants
Start Date 2025-11-18
Primary Completion 2026-08-03 (estimated)
Study Completion 2026-11-22 (estimated)
Updated on ClinicalTrials.gov 2026-01-28